10-K: scPharmaceuticals Inc. 2023 Annual Report: FUROSCIX Commercialization and Pipeline Expansion

scPharmaceuticals Inc.'s 2023 annual report highlights the commercial launch of FUROSCIX, positive FDA feedback on pipeline expansion, and financial results reflecting ongoing investment in growth.

Summary

• scPharmaceuticals Inc. is focused on developing and commercializing products that optimize the delivery of infused therapies, with a focus on subcutaneous administration.
• Their approved product, FUROSCIX, is a subcutaneous loop diuretic for treating fluid overload in adults with chronic heart failure, and its commercial launch began in the first quarter of 2023.
• The company received positive FDA feedback for expanding the FUROSCIX indication to include NYHA Class IV heart failure patients and for developing an 80mg/1mL auto-injector.
• They also plan to submit a supplemental new drug application (sNDA) in the second quarter of 2024 to expand the indication to include treatment of edema due to fluid overload in patients with chronic kidney disease (CKD).
• The estimated total addressable market opportunity for FUROSCIX in the U.S. is $12.5 billion, including both chronic heart failure and CKD.
• The average cost of treatment with FUROSCIX is estimated at $4,490 per episode, which is significantly lower than the cost of a single hospitalization.
• As of December 31, 2023, approximately 30,000 FUROSCIX doses were written by around 1,700 unique prescribers, with approximately 16,000 doses filled.
• The company incurred a net loss of $54.8 million for the year ended December 31, 2023, and has an accumulated deficit of $281.3 million.
• The company believes its existing cash, cash equivalents and short-term investments will be sufficient to fund operations for at least the next 12 months.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While there are positive developments in product commercialization and pipeline expansion, the company's financial losses and reliance on future funding create uncertainty. The sentiment is neutral to slightly negative.

Positives

• FUROSCIX is the first and only FDA-approved subcutaneous loop diuretic that delivers IV equivalent diuresis at home.
• The company has secured positive coverage and preferred formulary status with a top five national commercial health plan and national Medicaid coverage.
• A major integrated delivery network (IDN) provides unrestricted access to FUROSCIX to over 8 million lives.
• The company received U.S. patents covering concentrated formulations of furosemide.
• The company believes its existing cash, cash equivalents and short-term investments will be sufficient to fund operations for at least the next 12 months.

Negatives

• The company has a history of significant operating losses and expects to incur significant and increasing losses for the foreseeable future.
• The company has a limited operating history and no history of commercializing pharmaceutical products.
• The company identified a material weakness in its internal control over financial reporting related to the fair value accounting associated with its derivative liability.

Risks

• The company is heavily dependent on the success of FUROSCIX and may not receive regulatory approval for other product candidates.
• Failure to produce FUROSCIX in required volumes or achieve market acceptance could hinder commercialization efforts.
• The company may need additional funding and may be unable to raise capital when needed.
• The company's success depends on its ability to protect its intellectual property and comply with obligations under intellectual property licenses.
• The company may be subject to product liability lawsuits related to its products and product candidates.
• The company depends heavily on its executive officers, directors and principal consultants and the loss of their services would materially harm the business.
• The company faces substantial competition from other pharmaceutical and biotechnology companies.
• The company's products and product candidates may have serious adverse, undesirable or unacceptable side effects which may delay or prevent marketing approval.

Future Outlook

The company expects to continue to incur net losses for the foreseeable future as it supports the commercialization of FUROSCIX and continues to develop new products and enhance existing technologies. The company believes its existing cash, cash equivalents and short-term investments will be sufficient to fund operations for at least the next 12 months.

Management Comments

• The company believes FUROSCIX will allow eligible patients with chronic heart failure and, if approved, chronic kidney disease with worsening congestion due to fluid overload, to receive IV-strength diuresis outside the high-cost hospital setting.
• The company believes FUROSCIX can potentially reduce the days per year that patients spend in the hospital to potentially avoid the need for unnecessary, expensive hospitalizations and thus reduce overall health care costs by decreasing both admissions and readmissions and improve patients quality of life through outpatient management of their fluid overload.

Industry Context

The announcement reflects a broader trend in the pharmaceutical industry towards developing and commercializing innovative drug delivery systems that can reduce healthcare costs and improve patient outcomes. The focus on subcutaneous administration aligns with the industry's push for more convenient and patient-friendly treatment options.

Comparison to Industry Standards

• The 99.6% bioavailability of FUROSCIX is a key differentiator compared to oral furosemide, which has highly variable absorption rates (10% to 100%).
• The company's focus on outpatient management of fluid overload aligns with the industry's shift towards reducing hospital readmissions and healthcare costs, similar to efforts by companies like Medtronic in remote patient monitoring.
• The development of an auto-injector for FUROSCIX is a strategic move to reduce manufacturing costs, similar to cost-reduction strategies employed by generic drug manufacturers.
• The company's commercialization strategy targeting a concentrated market of 600 hospitals and associated clinics is similar to the focused approach used by specialty pharmaceutical companies like Horizon Therapeutics.
• The company's reliance on third-party manufacturers is a common practice in the pharmaceutical industry, similar to companies like Catalent and Lonza, but it also introduces supply chain risks.

Stakeholder Impact

• Shareholders: The company's financial performance and future funding needs may impact shareholder value.
• Employees: The company's growth and expansion may create new opportunities for employees.
• Customers: The commercialization of FUROSCIX may provide a new treatment option for patients with fluid overload.
• Suppliers: The company's reliance on third-party manufacturers may impact suppliers.
• Creditors: The company's debt obligations and financial performance may impact creditors.

Next Steps

• Submit a sNDA in the second quarter of 2024 to expand the FUROSCIX indication to include treatment of edema due to fluid overload in patients with CKD.
• Initiate a pharmacokinetic/pharmacodynamic (PK/PD) study for the 80mg/1mL auto-injector in the second quarter of 2024.
• Submit a supplemental new drug application (sNDA) for the 80mg/1mL auto-injector in the fourth quarter of 2024.
• Continue to expand commercial infrastructure to support the sales and marketing of FUROSCIX.

Key Dates

Keywords

FUROSCIX, subcutaneous, loop diuretic, heart failure, chronic kidney disease, commercialization, FDA approval, pharmaceutical, drug delivery, clinical trials